Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3- yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5- dihydropyridazin-3(2H)-one], dobutamine, and milrinone: Comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 1, 2008, Pages 331-340

  Segreti, Jason A ^a   Marsh, Kennan C ^a   Polakowski, James S ^a   Fryer, Ryan M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 AMINOPHENYL) 5 METHYL 4,5 DIHYDROPYRIDAZIN 3(2H) ONE; DOBUTAMINE; DRUG METABOLITE; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; OR 1855; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG MEGADOSE; DRUG POTENCY; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; PULSE RATE; RAT; VASCULAR RESISTANCE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CARDIOVASCULAR PHYSIOLOGY; DOBUTAMINE; DRUG COMBINATIONS; HEART RATE; HEMODYNAMICS; HYDRAZONES; MALE; MILRINONE; MYOCARDIAL CONTRACTION; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE;

EID: 41149083577     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.132530     Document Type: Article

References (40)

1. 2+ current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol 435:27-33.
2. Akosah KO, Denlinger B, and Mohanty PK (1999) Safety profile and hemodynamic responses to beta-adrenergic stimulation by dobutamine in heart transplant patients. Chest 116:1587-1592.
3. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, and Scheinin H (2004) Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 23:213-222.
4. Antila S, Sundberg S, and Lehtonen LA (2007) Clinical pharmacology of levosimendan. Clin Pharmacokinet 46:535-552.
5. Antoniades C, Tousoulis D, Koumallos N, Marinou K, and Stefanadis C (2007) Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther 114:184-197.
6. 2 consumption in dogs. Am J Physiol Heart Circ Physiol 294:H238-H48.
7. Chatterjee K (1987) "Unloading" therapy for heart failure. West J Med 147:324-325.
8. De Luca L, Colucci WS, Nieminen MS, Massie BM, and Gheorghiade M (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27:1908-1920.
9. 2+ sensitizers-update 2001. Cardiovasc Drugs Ther 15:397-403.
10. Endoh M (2002) Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40:323-338.
11. Endoh M and Hori M (2006) Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother 7:2179-2202.
12. Ca channels in rat isolated arterioles. Br J Pharmacol 148:696-702.
13. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196-202.
14. ATP channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts. J Mol Cell Cardiol 33:831-834.
15. + channels and myocardial preconditioning. Circ Res 84:973-979.
16. ATP channels: triggers or distal effectors of ischemic or pharmacological preconditioning? Circ Res 87:431-433.
17. Haikala H, Kaheinen P, Levijoki J, and Linden IB (1997) The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34:536-546.
18. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, and Linden IB (1995) Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25:794-801.
19. Kaheinen P, Pollesello P, Levijoki J, and Haikala H (2001) Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37:367-374.
20. Kivikko M, Antila S, Eha J, Lehtonen L, and Pentikainen PJ (2002) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40:465-471.
21. Kivikko M and Lehtonen L (2005) Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 11:435-455.
22. ATP channel opener. Eur J Pharmacol 428:311-314.
23. Kopustinskiene DM, Pollesello P, and Saris NE (2004) Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 68:807-812.
24. ++-sensitizers for the treatment of heart failure. Curr Opin Crit Care 9:337-344.
25. Lilleberg J, Sundberg S, and Nieminen MS (1995) Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 26 (Suppl 1):S63-S69.
26. Liu G, Zhao H, Liu B, Xin Z, Liu M, Serby MD, Lubbers NL, Widomski DL, Polakowski JS, Beno DW, et al. (2007) Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases. Bioorg Med Chem Lett 17:495-500.
27. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, and Kivikko M (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. J Am Med Assoc 297:1883-1891.
28. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422-1432.
29. Ng TM and Akhter MW (2005) Levosimendan: dual mechanisms for acute heart failure and beyond? Minerva Cardioangiol 53:565-584.
30. Pataricza J, Hohn J, Petri A, Balogh A, and Papp JG (2000) Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 52:213-217.
31. Pataricza J, Krassoi I, Hohn J, Kun A, and Papp JG (2003) Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17:115-121.
32. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269:28584-28590.
33. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30:1115-1128.
34. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, Komajda M, and Gheorghiade M (2007) Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99:4A-23A.
35. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, et al. (2001) Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 276:9337-9343.
36. Szilágyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, and Papp Z (2004) The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486:67-74.
37. 2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 366:440-448.
38. Virág L, Hala O, Marton A, Varro A, and Papp JG (1996) Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer. Gen Pharmacol 27:551-556.
39. + channel in rat arterial myocytes. Eur J Pharmacol 333:249-259.
40. + channel in rat ventricular cells. J Pharmacol Exp Ther 283:375-383.